• John D Markman, William A Barbosa, Jennifer S Gewandter, Maria Frazer, Shirley Rast, Michelle Dugan, Kiran Nandigam, Armando Villareal, and Tai C Kwong.
• Department of Neurosurgery, University of Rochester, New York, 14642, USA.
• Pain Med. 2015 Jun 1;16(6):1132-6.

ObjectiveTo determine whether the prevailing liquid chromatography and tandem mass spectroscopy assay (LC-MS/MS) assay designed to monitor buprenorphine compliance of the sublingual formulation used in the substance abuse treatment setting can be extrapolated to the transdermal formulation used in the chronic pain treatment setting, which is 1000-fold less concentrated.DesignRetrospective chart review.SubjectsSelf-reported compliant patients using the transdermal or sublingual formulations of buprenorhphine. Transdermal patch application was also visually confirmed during clinic visits.MethodsUrine drug test results from a LC-MS/MS were compared between samples from transdermal and sublingual patients.ResultsWhile all sublingual patients tested positive for at least one metabolite of buprenorphine, only 69% of the transdermal patients did so. In addition, the most abundant metabolite in the transdermal patients was buprenorphine-glucuronide, as compared with norbuprenorphine-glucuronide in sublingual patients.ConclusionsThese data suggest that currently available urine drug tests for buprenorphine, including the more expensive LC-MS/MS based assays, may not be sufficiently sensitive to detect the metabolites from transdermal buprenorphine patients. This study highlights the need to evaluate the value and sensitivity of urine drug tests given the wide range of buprenorphine dosing in clinical practice. These results underscore the need for additional cost benefit analyses comparing different confirmatory drug testing techniques including many commercially available drug testing options. © 2014 Wiley Periodicals, Inc.Wiley Periodicals, Inc.

33 keywords...

hide…